BenevolentAI
AI-enabled drug discovery
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Enterprise
- Biology
- Machine Learning
- Science
- Fitzrovia, London, UK
Jump to section
Company mission
To unlock the power of AI to transform drug discovery and bring effective medicines to every patient.
Our take
There is a lot of research being done in the pharmaceutical industry, with BenevolentAI saying there's a new research paper published every 30 seconds. But the company argues that this information is not being used in a smart way for the discovery and development of new drugs.
To tackle this problem, BenevolentAI uses AI to analyse biomedical information, from clinical trials data to academic papers. This is used to identify molecules that have failed in clinical trials and predict how these same compounds could be more efficient targeting other diseases.
This approach could dramatically accelerate the discovery of new drugs, which makes it a very valuable proposition. BenevolentAI has collaborated with large pharma companies like AstraZeneca and Janssen Pharmaceutica, and raised significant funding to power R&D.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Work from home opportunities
Funding (last 2 of 3 rounds)
Sep 2019
$90m
LATE VC
Apr 2018
$115m
LATE VC
Total funding: $305m
This company has top investors
Leadership
Ivan Griffin
(Chief Business Officer & Founder)Former COO of the company. Worked as a Venture Capitalist for over a decade. Also helped launch Genomics England, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013.